NEWS - Mar 27, 2025 Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update Read more
NEWS - Mar 26, 2025 Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025 Read more
NEWS - Mar 25, 2025 Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. Read more
NEWS - Feb 6, 2025 Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB Read more
NEWS - Dec 9, 2024 Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017 Read more
NEWS - Dec 4, 2024 Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance Read more
NEWS - Nov 19, 2024 Relmada Therapeutics to Present at Jefferies London Healthcare Conference Read more
NEWS - Nov 14, 2024 Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease Read more
NEWS - Nov 7, 2024 Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Read more
NEWS - Nov 4, 2024 Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 Read more
